chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pt recv vax approx 4PM 3SEP98 & started w/low grade fever @ 5PM 3SEP98;c/o sore throat 7AM 4SEP98;no redness @ inj site;
SERVA. that started around two (2) days after injection.  Numbness and tingling in left arm predominately from wrist to finger tips.  The numbness in no longer as acute as initially but is still there.    Mostly it is just numbness in my left hand from wrist to finger tips with loss of sensitivity most noticeably in the tips the three (3) long fingers.  Gripping  creates a unique sensation kind of like have a carbonated beverage in my muscle tissue.    There isn't anything to do presently but to wait.
I received my first COVID 19 Pfizer Vaccine on 7/22/21. I woke up at 5am on 7/23/21 having pain with urination.  I?ve had a UTI before (approximately 2-3 years ago) and recognized the symptoms. I bought cranberry juice, Azo, and cranberry extract capsules. I am currently treating it at home but will visit a doctor if symptoms don?t clear up in a day or two.
This spontaneous report as received from a nurse refers to a 12 year old patient. No information regarding the patient's medical history was provided. On 11-SEP-2013 the patient was vaccinated with VARIVAX (Merck) 1350 U, 0.5 ml subcutaneously, with valid lot # 1409AA. The vaccine had been expired on 03-SEP-2013 (reported as 06-SEP-2013 as well). No concomitant medication was reported. No adverse events were reported. No outcome was reported. This case was linked to case # 1309USA008745 (same reporter). Additional information has been requested.
On 4/6/23 Pt. woke up covered in red spots, slightly raised,  no heads/swelling/peeling, and he had a 101.1 fever.  He would only take formula and some water.  We did not administer any medicine.  That night, he was really hot, had trouble sleeping, and a temp of 100.4.  The morning of 4/7/23, his spots turned into large patches of red all over his body, including face, tops of hands, and tops of feet, still slightly raised, and very hot to touch.  He barely had any areas that weren?t red.  His fever peaked at 102.7 and he was very lethargic, wouldn?t nap, and obviously felt bad .  I gave Tylenol once that evening and a cool bath.  He slept a little better that night.  This morning, 4/8/23, his fever is gone, he?s acting a bit better, and most of the redness is lightened and no longer raised or hot.  The doctor was closed during this because of holiday/weekend; we almost went to the ER.
Mother states child developed a staring spell for 2-3 days with occasional shaking-stopped cooing-lost grasp grasping resumed in 10-14 days.
Left axillary lymph node swelling and tenderness, left deltoid muscle tenderness, symptoms started 48 hours after injection and already improved after another 24 hours.
pt recvd vax & exp t105 ax; referred to hosp given APAP/advised of sz risk; not seen in ER;
Fever, nausea, headache, lethargic, pain at injection site, abdominal cramping
Tested positive for COVID 19 08/21/2020. About 2 weeks after 2nd dose, I began to experience dizziness, nausea, tunnel vision, and post exertional malaise. My symptoms steadily declined throughout the summer including muscle weakness, discoordination of lower extremities, and loss of ability to walk. I developed Post Viral Fatigue Syndrome and Long COVID.
Was a little sore at injection site.  Some mild flu-like symptoms for 48 hours after BOTH injectionsvaccinations (March 5, 2021, 2nd shot on April 2, 2021).  All was well until about 4-6 weeks ago, I started noticing soreness in elbows and knees.  This is general soreness that did not immediately cause concern.  I'm fairly active and assumed it was due to over exertion beyond normal activity.  Soreness has persisted for las 4-6 weeks.
muscle weakness,  shakiness,  some tingling  occasional heart racing Hospital stay February 28-March 2  for heart tests- found no heart issue. Saw neurologist on May 13th, no findings other than vaccine reaction. Symptoms worsened after second dose.
pt recv vax 12AUG97 & 25AUG97 pt devel shingles consisting of 2-3 erythematous lesions @ the site of inj on the lt upper arm @ the C6 dermatome;
77 patients received Moderna bivalent booster doses that had undergone a temperature excursion; Product storage error; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (77 patients received Moderna bivalent booster doses that had undergone a temperature excursion), PRODUCT STORAGE ERROR (Product storage error) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7140C) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (77 patients received Moderna bivalent booster doses that had undergone a temperature excursion), PRODUCT STORAGE ERROR (Product storage error) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (77 patients received Moderna bivalent booster doses that had undergone a temperature excursion), PRODUCT STORAGE ERROR (Product storage error) and NO ADVERSE EVENT (No adverse event) outcome was unknown. Not Provided      The action taken with mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) was unknown.   For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (77 patients received Moderna bivalent booster doses that had undergone a temperature excursion) and PRODUCT STORAGE ERROR (Product storage error).    It was reported that 77 patients received Moderna bivalent booster doses that had undergone a temperature excursion. The doses were administered before it was known if the vaccine was ok to use after the excursion. This case is for 39th patient out of 77 patients reported. No concomitant medication information provided. No treatment information provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-696122.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-696122:Master case
Patient's mother stated: patient was fine until about 10 minutes post-dose, she stated he was slightly shaking, his eyes were rolling around and he was drooling and had nasal discharge. The mother stated he has never done this before and the 1st COVID vaccine dose went good. I was made aware ~30 minutes post-dose and went outside to check on the patient, he seemed to be doing fine at that point.
Received flu shot in left arm on 10/23/03.  Noticed on 11/12/03 arm was sore, dime sized red spot, tissue more firm.
Information has been received from a physician, author of the article, regarding a healthy 22-month-old boy presented (patient #1) who presented with a history of 11 episodes of nonbloody, nonbilious emesis occurring over a 2-hour period. He was treated with oral ondansetron, orally rehydrated, and discharged. The patient returned 8 hours later with persistent vomiting. Because he was tachycardic and dehydrated, he received intravenous fluids overnight and was discharged the next day. Although the patient had received no doses of rotavirus vaccine, his infant sibling received a second dose of ROTATEQ 7 days prior to the patient's illness onset. The VP7 G1 gene of ROTATEQ component strain WI79-9 (G1P [5]) (99.9% identity in 839 bases sequenced) and the VP4 P[8] (100% identity in 835 bases) and VP6 I2 (100% identity in 338 bases) genes from RV5 strain WI79-4 (G6P[8]) were detected in a fecal specimen obtained 2 days after illness onset. Rotaviruses and unidentified particles 30-40 nm in diameter were observed. This patient illustrate a spectrum of potential clinical and virologic outcomes associated with routine use of live, attenuated rotavirus vaccines. The diversity of these occurrences include apparent transmission of an ROTATEQ vaccine-reassortant-strain from a vaccinated infant to an unvaccinated sibling (patient 1). Although these findings suggest potentially unusual transmission or vaccine replication processes, the contribution of the vaccine or vaccine-reassortant strain to patient's illness is unclear. Patient's illness was clinically consistent with rotavirus acute gastroenteritis (AGE) and occurred after exposure to a younger sibling who had recently received ROTATEQ. This patient's history of exposure and subsequent illness is similar to a prior report of sibling transmission of the same vaccine-derived G1P [8] strain [8], supporting the likely linkage between this vaccine reassortant strain and patient's illness. Additional information has been requested. This is one of several reports received from the same source.
c/o sore upper lt arm @ inject site; recvd flu inject 4DEC91 denies swelling, redness; currently arm is stiff & painful when getting up in PM; sx remain the same since day of inject; advised to see MD for eval of lt arm;
On an unspecified date after getting the 1st dose, got sick for a week; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (On an unspecified date after getting the 1st dose, got sick for a week) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In May 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In June 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ILLNESS (On an unspecified date after getting the 1st dose, got sick for a week). At the time of the report, ILLNESS (On an unspecified date after getting the 1st dose, got sick for a week) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown, dechallenge unknown, rechallenge positive.  Treatment information was not provided.   This case was linked to MOD-2021-319876 (Patient Link).; Sender's Comments: This case concerns a 63-year-old, female patient with unknown medical history, who experienced the unexpected non-serious event of illness was noticed after first dose and unexpected non-serious events of illness, short of breath, fever, sinusitis, and ear infection after second dose.  The rechallenge is noticed for illness. The reporter did not provide the causality assessment. The benefit-risk relationship of Spikevax in not affected by this report.  NOTE:: The case has another case  (non-serious MOD-2021-319876) registered for the events after second dose.
This spontaneous report as received from medical assistant refers to unspecified patients of unknown demography. On an unknown date, the patients were vaccinated with improperly stored VARIVAX lot # M000757 (expiry: 06-JAN-2018). It was reported that the vaccine reached -14.1 C for 20 minutes. They also had a prior excursion reaching 9 F for 10 hours. There details were captured by a data logger and the vaccine was back in range. No adverse effects were reported. No product quality complaint (PQC) involved. This case is linked to the case 1608USA012594 (same reporter link). Additional information has been requested.
Patient did not go back to receive his second shot of the Moderna Covid-19 vaccine/Greater than 35 days in between doses of the Moderna Covid-19 vaccine.; Could hardly move after first dose of his primary series; Muscle and body aches; This spontaneous case was reported by a patient and describes the occurrence of MOBILITY DECREASED (Could hardly move after first dose of his primary series), MYALGIA (Muscle and body aches) and PRODUCT ADMINISTRATION INTERRUPTED (Patient did not go back to receive his second shot of the Moderna Covid-19 vaccine/Greater than 35 days in between doses of the Moderna Covid-19 vaccine.) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jun-2021, the patient experienced MOBILITY DECREASED (Could hardly move after first dose of his primary series) and MYALGIA (Muscle and body aches). On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (Patient did not go back to receive his second shot of the Moderna Covid-19 vaccine/Greater than 35 days in between doses of the Moderna Covid-19 vaccine.). At the time of the report, MOBILITY DECREASED (Could hardly move after first dose of his primary series), MYALGIA (Muscle and body aches) and PRODUCT ADMINISTRATION INTERRUPTED (Patient did not go back to receive his second shot of the Moderna Covid-19 vaccine/Greater than 35 days in between doses of the Moderna Covid-19 vaccine.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  The height of the patient reported as 5 feet 7 inches.  The patient received his first shot of the Moderna Covid-19 vaccine on 15-Jun-2021 and did not go back to receive their second shot of the Moderna Covid-19 vaccine and it had been greater than 35 days in between doses of the Moderna Covid-19 vaccine.  The patient did not remember which arm he received the vaccine in.  The patient did not report taking any Medications and did not report any disease states.  No treatment information was provided by the reporter.
really sick with type A flu; Initial information received on 25-Dec-2022 regarding an unsolicited valid social media non-serious case received from a consumer/non-HCP.  This case involves male patient who was really sick with type a flu after receiving vaccine influenza vaccine.  It is unknown if the patient had any medical history, concomitant disease or risk factor.  The patient's medical treatment(s), vaccination(s), and family history were not provided.   On an unknown date, the patient received a dose of suspect influenza vaccine produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for flu (strength, formulation, dose and expiry date: unknown).  On an unknown date the patient was really sick with type a flu (influenza) (unknown latency) following the administration of influenza vaccine.  It is unknown if there were lab data/results available.  Action taken: not applicable  It was not reported if the patient received a corrective treatment for the event (really sick with type A flu).  At time of reporting, the outcome was Unknown for the event really sick with type a flu.
tachycardia,chills, allover ill feeling   Could not get in to see any doctor or Urgent Care.  Used system to talk to doctor.  Was awoken from sound sleep by racing heartbeat and chills.  Lasted approx 10 hours.
Information has been received from a physician concerning a 15 year old female who on 10-AUG-2007 was vaccinated IM with a first dose of Gardasil (Lot # 658222/0927U).  Concomitant vaccination included MENACTRA.  On 10-AUG-2007 the patient felt woozy after the vaccination but didn't feel completely faint.  It was reported that the patient had not eaten all day.  The physician had the patient stay for an hour.  The patient left the office fully recovered.  Additional information has been requested.
cough, congestion, nasal drainage, elevated Heart rate 100-120's, redness and swelling in RUE from elbow to shoulder
Only received one dose of the moderna vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Only received one dose of the moderna vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Only received one dose of the moderna vaccine). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Only received one dose of the moderna vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment and concomitant medications were provided.  The patient received only one dose of the Moderna vaccine, patient did not state why she did not get the second dose, but she was calling about getting it now.
This spontaneous report as received from a company representative via physician refers to a 4 months old patient. On an unknown date, 4 months old patient received first dose of ROTATEQ. No other co-suspects were reported. No concomitant medications were reported. No treatment information was reported. No adverse event reported. Additional information is not expected.
Heavy bleeding with clots TWO MONTHS EARLY ( normally only 4 prds a yr) Weakness in legs Twitching in legs Muscle spasms in legs Severe Pain from waist dow Difficulty walking
The morning after vaccine, pt. felt physically ill. He was exhausted, sore, and stated he didn't know if he ran a fever. He was nauseated but mostly whole body soreness. He felt better after about 36 hours. Didn't go to doctor.
administered expired vaccine to the patient, after the manufacture date of expiration; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered expired vaccine to the patient, after the manufacture date of expiration) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (administered expired vaccine to the patient, after the manufacture date of expiration). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administered expired vaccine to the patient, after the manufacture date of expiration) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported.  It was reported as unknown when the vial was initially stored in the refrigerator.  The vial did not undergo any temperature excursions.  Treatment information was not reported.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2022: The follow up information received includes non-significant information updated.
Symptom onset was on 09/18/2021. Symptoms included cough, loss of taste, loss of smell, diarrhea, fatigue and chills. Case was hospitalized from 9/18/2021 through 09/26/2021.
pt recv vax 6DEC96 & same day pt devel a local rxn consisting of a hematoma @ the inj site & blisters;
Bell's Palsy. Paralysis on right side of face. Diagnosed 10-14-13. Treatment-Predisone and anti-viral medication-Valacyclovir HCL 1 gram. Originally, I had a reaction to the shot at the location of the shot in the upper arm and the reaction covered about 1/2 of my upper arm. The reaction occurred the next day and it was red, itchy and sore for about 1 week after the shot in May, 2013. I called the pharmacy and they said it was normal for some people and not to worry.
Information has been received from a registered nurse and a nurse practitioner concerning an 8 year old male child with no past medical history who on 12/27/96 was vaccinated SC in the right arm with a first dose of varicella virus vaccine live (lot # 620620/1107D). There was no illness at the time of vaccination. There was no concomitant medication. On 6/29/03 (also reported as 7/1/03) the patient broke out in 80-100 varicella lesions/vesicles and developed a fever. It was reported that the patient developed breakthrough chicken pox. Unspecified medical attention was sought and no treatment was required/provided. No laboratory diagnostic tests were performed. Subsequently, the patient recovered. No further information is expected.
Hives starting at injection site that spread to entire body. Was relieved with Benadryl orally.
Pt was adm to hosp on 19SEP91 due to 3 febrile seizures; On 17SEP91 pt recvd DTP/HIB & devel low grade fever, generalized tonic  sz lasting 40 seconds; T100.4 R;
09/28/2021, the day after the vaccine, I noticed a flutter in my throat like a palpitation, and just palpitations. I was having upper back pain that was  radiating to my chest.   Everything else was pretty normal. And it continued throughout the week until Monday, 10/11/2021.  On 10/11/2021-The doctor did an EKG trying to figure out why my heart rate was so high. I have general anxiety, but she was still concerned because it is never gets that high. On 10/11/2021- She put a heart monitor on me for 7 days to monitor it.  The fluttering I was experiencing has calmed down, and I will know the results of my heart rate,  when the doctor gets the results back from the heart monitor.
4/4/2021-Low grade fever 101, fatigue, headache 4/7/2021- gums started to bleed, saw Dentists and to watch for 2 weeks 4/14/201 had Stroke- Left side brain-
1/20/2021 staff had , muscle aches, body aches migraine. 1/26/2021 went to ER with Left sided weakness and fell. DX complex migraines.
Beginning about 6 to 7 hours after administration developed pain radiating from right arm from injection site, fingers of right hand became swollen. Swelling persisted into 12/22 with decreased strength of hand. Hand returned to normal 12/23 but still pain upper arm at site of injection.
This spontaneous report as received from the physician's office via medical assistant and via company representative refers to a currently 46 year old female patient. In April 2005, reported as 10 years ago, when the patient was 36 years of age, she was vaccinated with two doses of VARIVAX (Merck) (dose, route,  lot #s not reported). On an unknown date the patient failed to seroconvert. On 25-FEB-2015 the titer test showed IgG immunoglobulin antibody titer was 45, which was negative, there was no antibody titer. The patient sought medical attention by seeing the physician. The outcome of the events was not reported. The causality between the events and VARIVAX (Merck) was not reported. Additional information has been requested.
pt recv vax 27FEB97 & 28FEB97 pt devel a fine red, raised rash over face, neck, stomach, & legs;itchiness;elevated temp of 99.2;
Post vax, the pt developed raised bright red rash on stomach, progressing then to shoulders. The pt had conjunctivitis that was treated with antibiotic eye drops. On 5/21, rash raised flesh colored on backs of elbows and faint rash on knees; he also had worsening of conjunctivitis. Pt was dx with possible viral infection.
8 days after first shot I woke Jan. 31  with sore and itchy arm at injection site and below. Lasted about two days.  Possible slight muscle atrophy corresponding to lower red itchy slash mark.
Jan 25: very painful shot, arm sore immediately. 26: sore arm all day. 27: sore arm, livid reaction, 3 inches by 2 inches (Grade 3 local reaction), flushed skin on face, malaise, headache and shivering, went to bed early with Ibuprofen. 28: headache, malaise, sore and itchy arm, hot compresses. 29-31: local reaction much less livid, sore and itchy arm but not as sore, mostly better by day's end. Feb 1: itchy and discolored arm.
Covid ?arm?.  Swelling, itching at site of vaccination 10 days after being vaccinated. Lasting approx 2 days.